Sapropterin

Drug Profile

Sapropterin

Alternative Names: 6R-BH4; BH4; Biopten; Kuvan; Phenoptin; Sapropterin dihydrochloride; SUN-0588; SUN0588r; Tetrahydrobiopterin

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Asubio Pharma; Daiichi Sankyo Company
  • Developer Asubio Pharma; BioMarin Pharmaceutical; Daiichi Sankyo Company; John Hopkins University
  • Class Anxiolytics; Nootropics; Pterins; Small molecules
  • Mechanism of Action Nitric oxide synthase stimulants; Phenylalanine hydroxylase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Phenylketonuria
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Phenylketonuria
  • Phase II Isolated systolic hypertension
  • Discontinued Coronary disorders; Hypertension; Kidney disorders; Peripheral arterial disorders; Pulmonary hypertension; Sickle cell anaemia; Vascular disorders

Most Recent Events

  • 19 Sep 2017 Sapropterin receives Orphan Drug status for Phenylketonuria in Australia
  • 17 Aug 2017 BioMarin Pharmaceuticals terminates a phase II trial in Isolated systolic hypertension (In adults, In the elderly) as no subjects were enrolled in the study in USA (PO) (NCT00802893)
  • 13 Apr 2017 BioMarin Pharmaceutical has patent protection for Sapropterin in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top